Altria Group's Q2 Performance: On! Nicotine Pouches Achieve Best Sales in a Year

Business by 2FIRSTS
Aug.05.2024
Altria Group's Q2 Performance: On! Nicotine Pouches Achieve Best Sales in a Year
Altria Group releases strong Q2 results for on! nicotine pouches and NJOY products, showing consistent growth in sales.

Recently, Altria Group, Inc. released its performance report for the second quarter and first half of 2024. In the second quarter, the shipment volume of on! nicotine pouches reached 41.2 million cans, an increase of 37.3% compared to the same period last year. Additionally, the total shipment volume of NJOY consumables and devices in the second quarter reached 14.3 million units.

 

2FIRSTS analyzed the market performance of Altria's nicotine pouch and NJOY over the past year, aiming to provide in-depth insights into their prospects in the smokeless tobacco/e-cigarette market.

 

Sales Volume of Nicotine Pouches Continues to Rise in Q4

 

The performance report for the second quarter and first half of 2024 from Altria Group indicates that the on! nicotine pouch, as a smokeless nicotine product, has seen consecutive growth in both shipments and market share in the U.S. oral tobacco market for four consecutive quarters.

 

Altria Group's Q2 Performance: On! Nicotine Pouches Achieve Best Sales in a Year
Mapping: 2FIRSTS

 

In particular, in the second quarter of this year, the total shipment volume of ON! nicotine pouches reached 41.2 million cans, an increase of 37.3% compared to the same period last year. They held a market share of 8.10% in the U.S. oral tobacco market, with a growth rate of 1.20% compared to the previous year.

 

In the first quarter of this year, ON! Nicotine pouches' total shipment volume reached 33.3 million cans, a YoY increase of 32.1%; occupying a 7.10% market share in the U.S. oral tobacco market, with a YoY growth rate of 0.70%.

 

Looking back at the fourth quarter of 2023, the total shipment volume of on! nicotine pouches was 30.4 million cans, an increase of 32.8% year-on-year. The market share was 6.90%, with a year-on-year growth rate of 1.10%.

 

In the third quarter of 2023, the total shipment volume of ON! nicotine pouches was 28.7 million cans, a year-on-year increase of 36.7%, with a market share of 6.90%, representing a year-on-year growth rate of 1.70%.

 

Up until the first half of 2024, the shipping volume of on! nicotine pouches has increased by 35% year-on-year.

 

Over the past four quarters, the shipment volume of ON! nicotine pouches has maintained a year-on-year growth rate of over 30%, and its overall market share has also been on the rise. Although the market share of the product in the U.S. smokeless tobacco market saw a decrease in the first quarter of this year compared to the same period last year, in the second quarter, both the shipment volume, year-on-year growth rate, and market share of ON! nicotine pouches reached their highest point in two years.

Altria Group's Q2 Performance: On! Nicotine Pouches Achieve Best Sales in a Year
Mapping: 2FIRSTS

2FIRSTS compared the market performance of On! nicotine pouches with ZYN, a nicotine pouch under the Phillip Morris International (PMI) brand, over the past year.

 

From the third quarter of 2023 to the first half of 2024, ZYN nicotine pouches have achieved four consecutive quarters of growth in the US market. Although the year-on-year and quarter-on-quarter growth rates decreased in the second quarter of 2024, the overall growth momentum remains strong. By the first half of 2024, the shipment volume of ZYN nicotine pouches has increased by 63.5% year-on-year.

 

Nicotine pouches, as a smokeless nicotine product, have gained high acceptance among American consumers, and this type of product has already achieved a significant market share in the American market.

 

NJOY Retail Market Share Reached 5.50%

 

Altria Group's Q2 Performance: On! Nicotine Pouches Achieve Best Sales in a Year
Mapping: 2FIRSTS

 

On June 1, 2023, Altria Group completed its acquisition of NJOY, achieving growth in sales by strengthening NJOY's global supply chain, filling retail inventory gaps, and expanding distribution channels.

 

Specifically, in the third quarter of 2023, NJOY's total shipment of devices and consumables reached 7.5 million units. By the fourth quarter of 2023, the shipment volume increased to 12 million units, representing a 60% quarter-on-quarter growth. At the same time, NJOY's market share in the United States rose to 3.70%.

 

In the first quarter of 2024, NJOY's shipment volume of devices and consumables slightly increased to 11.9 million units, representing a 0.6% increase from the previous quarter. The retail market share also further increased to 4.30%.

 

In the second quarter of 2024, the shipping volume significantly increased to 14.3 million units, a sequential growth of 1.3%, with a retail market share reaching 5.50% and a continued growth in market share.

 

According to the data, NJOY maintained growth in shipments from the fourth quarter of 2023 to the second quarter of 2024, while steadily increasing its retail market share in the U.S. e-cigarette market.

 

Altria Group's second quarter and first half performance report also showed that in the first half of 2024, the group's net revenue decreased by 3.6% to $11.8 billion, with revenue excluding excise taxes decreasing by 2.0% to $10 billion. The main reason for the decline in revenue was a decrease in revenue from the smokeable products segment, but this was partially offset by an increase in revenue from the oral tobacco products segment.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Irish Government Approves Ban on Disposable Vapes and Tightens Nicotine Controls
Irish Government Approves Ban on Disposable Vapes and Tightens Nicotine Controls
Irish Government has approved the Public Health (Single Use Vapes) Bill 2025, which will outlaw the sale of disposable e-cigarettes and introduce tighter restrictions on other nicotine products such as pouches. The move follows Northern Ireland’s similar ban earlier in 2025 and aims to protect young people from nicotine addiction.
Nov.20 by 2FIRSTS.ai
China Qingdao Jiaodong Airport Customs Seizes 430 Disposable E-Cigarettes and 8600ml of E-Liquid
China Qingdao Jiaodong Airport Customs Seizes 430 Disposable E-Cigarettes and 8600ml of E-Liquid
Qingdao Jiaodong Airport customs seized 430 disposable e-cigarettes with 8600ml e-liquid, exceeding personal duty-free limits. Items detained for legal processing.
Oct.14 by 2FIRSTS.ai
JT Launches Ploom CUBE Heated Tobacco Device Featuring SMART HEATFLOW
JT Launches Ploom CUBE Heated Tobacco Device Featuring SMART HEATFLOW
Japan Tobacco has launched the Ploom CUBE heated-tobacco device in Japan, with a starter kit retail price of JPY 1,980 (approximately US$13). The cube-shaped device employs the same SMART HEATFLOW heating technology as Ploom AURA and delivers roughly 19–27 sticks per charge.
Oct.09 by 2FIRSTS.ai
2Firsts Exclusive | AVM President Allison Boughner: The U.S. Vape Market Reshapes Under a Regulatory Storm
2Firsts Exclusive | AVM President Allison Boughner: The U.S. Vape Market Reshapes Under a Regulatory Storm
Amid intensified regulation and sweeping market shifts, the U.S. vaping industry is undergoing a profound transformation. In an exclusive interview with 2Firsts, AVM President Allison Boughner discusses how enforcement is reshaping brands, distribution, products, compliance, and U.S.-based manufacturing.
Oct.20
Illegal Vape Sellers in the Netherlands Could Be Fined Up to €4,040
Illegal Vape Sellers in the Netherlands Could Be Fined Up to €4,040
The outgoing Dutch government plans to raise fines for illegal sales of vapes and cigarettes, with first-time offenders facing a €2,040 penalty. The new fines, up to €4,040 for large companies, are expected to take effect on July 1, 2026, pending parliamentary approval.
Nov.10 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai